CAPR → $75.00 by Jun 9, 2025.

Despite trading at **$12.77**, CAPR’s fair value should be between **$75 and $200+** based on **expected Deramiocel pricing, revenue share, and industry valuation multiples**. At an estimated **$1M per patient per year** and **30-50% revenue share with Nippon Shinyaku**, Capricor’s cut could be **$750M–$1.25B annually**. Applying a standard **biotech multiple of 5-10x peak revenue**, CAPR’s market cap should be **$3.75B–$12.5B**, translating to **$75–$250 per share** (vs. \~$580M market cap today). # Stock Holding Strong Despite Market Selloff Since my **March …